# Awesome-P450  
[![Awesome](https://awesome.re/badge.svg)](https://awesome.re)

ğŸ”¥ **Boost up AI 2025 â€“ CYP3A4 Inhibition Prediction** ê²½ì§„ëŒ€íšŒì™€ CYP450-AI ì—°êµ¬ë¥¼ ìœ„í•œ ë…¼ë¬¸Â·ë°ì´í„°Â·ì½”ë“œÂ·íŠœí† ë¦¬ì–¼ íë ˆì´ì…˜.

<p align="center">
  <img src="docs/banner_cyp3a4.png" width="65%">
</p>

---

## ëª©ì°¨
- [ë°°ê²½](#ë°°ê²½)
- [ëŒ€íšŒ ê°œìš”](#ëŒ€íšŒ-ê°œìš”)
- [í‰ê°€ ì§€í‘œ](#í‰ê°€-ì§€í‘œ)
- [ë°ì´í„°ì…‹](#ë°ì´í„°ì…‹)
- [Milestone Papers](#milestone-papers)
  - [1. Biochemistry & Structural](#1-biochemistry--structural)
  - [2. Assay & HTS](#2-assay--hts)
  - [3. QSARâ€Š/â€ŠML](#3-qsar--ml)
  - [4. GNNâ€Š/â€ŠDL](#4-gnn--dl)
  - [5. Benchmark Datasets](#5-benchmark-datasets)
- [Starter Kits & ë² ì´ìŠ¤ë¼ì¸](#starter-kits--ë² ì´ìŠ¤ë¼ì¸)
- [Trainingâ€Š/â€ŠInference íˆ´](#trainingâ€Š/â€Šinference-íˆ´)
- [í‰ê°€Â·ìœ í‹¸ë¦¬í‹°](#í‰ê°€Â·ìœ í‹¸ë¦¬í‹°)
- [ê°•ì˜ & íŠœí† ë¦¬ì–¼](#ê°•ì˜--íŠœí† ë¦¬ì–¼)
- [ê¸°ì—¬ ë°©ë²•](#ê¸°ì—¬-ë°©ë²•)
- [ë¼ì´ì„ ìŠ¤](#ë¼ì´ì„ ìŠ¤)

---

## ë°°ê²½
- **CYP3A4**: ì¸ê°„ ê°„â€§ì†Œì¥ì— ê°€ì¥ í’ë¶€í•œ P450 ì´ì†Œíš¨ì†Œ â†’ í—ˆê°€ ì˜ì•½í’ˆì˜ 30 ~ 50 % ëŒ€ì‚¬  
- **ëª©í‘œ**: í™”í•©ë¬¼ 1,681ì¢…ì˜ **SMILES + ì €í•´ìœ¨(%)** ë°ì´í„°ë¡œ ICâ‚…â‚€ ëŒ€ì‹  %inhibition íšŒê·€ ëª¨ë¸ì„ ë§Œë“¤ê³  **Normalized RMSE + Pearson r** í˜¼í•© ì ìˆ˜ë¡œ ê²½ìŸ  
- **ì£¼ìµœ**: êµ­ê°€ìƒëª…ì—°êµ¬ìì›ì •ë³´ì„¼í„° (NBRIC)  
- **ê¸°ê°„**: 2025-05-01 ~ 2025-07-31  

## ëŒ€íšŒ ê°œìš”
| í•­ëª© | ë‚´ìš© |
|------|------|
| ì£¼ì œ | **CYP3A4 ì €í•´ìœ¨(%) ì˜ˆì¸¡ íšŒê·€ ëª¨ë¸** |
| ì œì¶œ íŒŒì¼ | `sample_submission.csv` â†’ `ID, Inhibition` |
| ì œì¶œ íšŸìˆ˜ | 1ì¼ ìµœëŒ€ 3íšŒ |
| ê³µì‹ í˜ì´ì§€ | ğŸ”— (ì¶”ê°€ ì˜ˆì •) |
| ì»¤ë®¤ë‹ˆí‹° | Discussions / Slack ì±„ë„ |

## í‰ê°€ ì§€í‘œ
| ê¸°í˜¸ | ì •ì˜ | ì‹ |
|------|------|---|
| **A** | Normalized RMSE |  ![nRMSE](docs/img/nrmse_formula.svg) |
| **B** | Pearson Correlation | Ï(Å·, y) |
| **Score** | ìµœì¢… ì ìˆ˜ | `0.5 Ã— (1 âˆ’ min(A, 1)) + 0.5 Ã— B` |

## ë°ì´í„°ì…‹
| íŒŒì¼ | í¬ê¸° | ì»¬ëŸ¼ |
|------|------|------|
| `train.csv` | 1,681 Ã— 3 | `ID`, `Canonical_SMILES`, `Inhibition`(%) |
| `test.csv` | â€” Ã— 2 | `ID`, `Canonical_SMILES` |
| `sample_submission.csv` | â€” Ã— 2 | ì œì¶œ ì˜ˆì‹œ |

EDA ë…¸íŠ¸ë¶: [`notebooks/eda.ipynb`](notebooks/eda.ipynb)

---

## Milestone Papers

### 1. Biochemistry & Structural
| ì—°ë„ | ë…¼ë¬¸ | ê¸°ì—¬ |
|------|------|------|
| 1986 | Beaune *et al.* **PNAS** | ì¸ê°„ CYP3A4 cDNA ìµœì´ˆ ê·œëª… |
| 2004 | Williams *et al.* **Science** | ì²« X-ray êµ¬ì¡° â†’ ë‹¤ì¤‘ ê¸°ì§ˆ í¬ì¼“ ì œì‹œ |
| 2025 | Li *et al.* **Nat Commun** | Cryo-EM + AIë¡œ ì„ íƒì  ì–µì œì œ ê²°í•© ëª¨í‹°í”„ í•´ì„ |

### 2. Assay & HTS
| ì—°ë„ | ë…¼ë¬¸ | ê¸°ì—¬ |
|------|------|------|
| 1998 | Ito & Houston **Clin Pharmacokinet** | ì¼€í† ì½”ë‚˜ì¡¸ ê¸°ì „-ê¸°ë°˜ ë¶ˆê°€ì—­ ì–µì œ ì‹¤í—˜ê³„ í™•ë¦½ |
| 2021 | Veith dataset ë°œí‘œ (TDC) | 12 k í™”í•©ë¬¼ HTS ICâ‚…â‚€ ê³µê°œ |

### 3. QSAR / ML
| ì—°ë„ | ë…¼ë¬¸ | ê¸°ì—¬ |
|------|------|------|
| 2006 | Ekins *et al.* **JCIM** | ë‹¤ì¤‘-í”„ë¡œë¸Œ QSAR, multitask ì•„ì´ë””ì–´ |
| 2023 | Zhang *et al.* **J Appl Toxicol** | RF/GBDT vs GCN ì„±ëŠ¥ ë¹„êµ |

### 4. GNN / DL
| ì—°ë„ | ë…¼ë¬¸ | ê¸°ì—¬ |
|------|------|------|
| 2021 | Nguyen-Vo **Front Pharmacol** | **DeepCYPs** FP-GNN, AUC 0.90+ |
| 2022 | Liu *et al.* **JAFC** | DL-ê°€ìƒ ìŠ¤í¬ë¦¬ë‹ìœ¼ë¡œ ì‹ì´ì„± ì–µì œì œ ë°œêµ´ |
| 2024 | Wang *et al.* **ICLR** | SMILES-Transformer ëŒ€ê·œëª¨ ì‚¬ì „í•™ìŠµÂ·íšŒê·€ SOTA |

### 5. Benchmark Datasets
| ë°ì´í„°ì…‹ | í¬ê¸° | Split | ì¶œì²˜ |
|----------|------|-------|------|
| **CYP3A4_Veith** | 12 k | Scaffold | Huang 2021 |
| **DeepCYPs-71k** | 71 k | Random/Scaffold | Nguyen-Vo 2021 |
| **MolData-CYP3A4** | 8 k | Time | Wang 2024 |

---

## Starter Kits & ë² ì´ìŠ¤ë¼ì¸
| í´ë” | ëª¨ë¸ | íŠ¹ì§• |
|------|------|------|
| `starter/xgb_fp` | **XGBoost + ECFP4** | ê°„ë‹¨Â·ê³ ì† CPU baseline |
| `starter/attentivefp` | **AttentiveFP** | 5-fold CV, scaffold split |
| `starter/mpnn` | **D-MPNN (PyG)** | AMP + OneCycleLR, GPU |

> `conda env create -f environment.yml` í›„ ë°”ë¡œ ì‹¤í–‰ ê°€ëŠ¥.

## Trainingâ€Š/â€ŠInference íˆ´
- **PyTorch Geometric / DGL** â€“ GNN êµ¬í˜„  
- **DeepChem / MolNet** â€“ QSAR ë°ì´í„° ë¡œë”  
- **Optuna / W&B Sweeps** â€“ HPO & ì‹¤í—˜ ì¶”ì   
- **vLLM / TensorRT-LLM** â€“ ëŒ€ìš©ëŸ‰ ëª¨ë¸ ì¶”ë¡  ìµœì í™”

## í‰ê°€Â·ìœ í‹¸ë¦¬í‹°
- `utils/metric.py` â€“ Normalized RMSE & Pearson r  
- `utils/scaffold_split.py` â€“ Bemis-Murcko scaffold split  
- `utils/visualize_error.ipynb` â€“ ì‹¤ì œ vs ì˜ˆì¸¡ ì‹œê°í™”

## ê°•ì˜ & íŠœí† ë¦¬ì–¼
- **DeepChem Drug Discovery** MOOC  
- **Graph ML for Molecules (Stanford CS 273)**  
- **ACoP CYP ì›Œí¬ìˆ** â€“ PBPK ì‹œë®¬ë ˆì´ì…˜ ì…ë¬¸

---

## ê¸°ì—¬ ë°©ë²•
1. PR ì „ì— `pre-commit run --all-files` ì‹¤í–‰  
2. **ë…¼ë¬¸Â·ë°ì´í„°Â·ì½”ë“œ** ì¶”ê°€ â†’ ê´€ë ¨ ì„¹ì…˜ í‘œ ê°±ì‹   
3. ì´ìŠˆ / Discussion íƒ­ì—ì„œ ì§ˆë¬¸Â·ì•„ì´ë””ì–´ ê³µìœ 

## ë¼ì´ì„ ìŠ¤
- ì½”ë“œÂ·ë¬¸ì„œ: **MIT License**  
- ëŒ€íšŒ ë°ì´í„°: ì£¼ìµœ ì¸¡ ë¹„ìƒì—…ì  ì—°êµ¬ìš© ë¼ì´ì„ ìŠ¤

